CAR-T Therapies
CAR-T therapies, based on reprogramming a patient’s own immune cells, are creating a transformation spanning hematological malignancies to solid tumors. Omega manages your CAR-T programs through the entire process — from apheresis to infusion, from acute toxicity management to fifteen-year long-term follow-up.
From Apheresis to Long-Term Follow-Up
The success of a CAR-T trial depends on the seamless coordination of cell collection, manufacturing, logistics, infusion, and post-infusion monitoring. Every link in the chain — identity verification, timing, temperature control, documentation — must be managed with equal rigor.
The Omega ecosystem brings central laboratory, biorepository, home care, and digital health platforms under one roof, offering a unique integration for CAR-T programs in Turkey and the region.
Our CAR-T Capabilities
Apheresis Coordination
Cell collection scheduling, site capacity planning, product acceptance criteria, and post-apheresis patient follow-up are coordinated from a single point.
Bridging Chemotherapy Management
Bridging chemotherapy protocols between apheresis and infusion are managed with patient eligibility assessment, timing, and toxicity monitoring.
Cryopreservation & Logistics
Liquid nitrogen (cryogenic) transport, continuous temperature monitoring, validated dry shippers, and product delivery acceptance processes are executed with Chain of Custody documentation.
Release Testing Coordination
Sterility, endotoxin, viability, CAR expression, and potency assays are coordinated with accredited laboratories, with results reported per protocol timelines.
CRS & ICANS Monitoring
Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) are managed per protocol, including grading tools and remote monitoring via the TURP digital platform.
Long-Term Follow-Up (15 Years)
Insertional mutagenesis surveillance and delayed toxicity monitoring requirements are met with longitudinal sample storage at the Omega Biorepository and annual follow-up visits.
From Patient to Product, from Product to Response
Patient eligibility verification and cell collection
Chemotherapy and lymphodepletion protocol
Manufacturing in the federated network, QC release, cryogenic transport
Cell infusion after conditioning
CRS/ICANS surveillance and long-term follow-up